ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends OBSV vs. MRNS, PMN, VRCA, SNYR, LEXX, AKTX, XLO, GDTC, BFRG, and JATTShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Marinus Pharmaceuticals (MRNS), ProMIS Neurosciences (PMN), Verrica Pharmaceuticals (VRCA), Synergy CHC Corp. (Uplisting) (SNYR), Lexaria Bioscience (LEXX), Akari Therapeutics (AKTX), Xilio Therapeutics (XLO), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Marinus Pharmaceuticals ProMIS Neurosciences Verrica Pharmaceuticals Synergy CHC Corp. (Uplisting) Lexaria Bioscience Akari Therapeutics Xilio Therapeutics CytoMed Therapeutics Bullfrog AI JATT Acquisition ObsEva (NASDAQ:OBSV) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Does the media refer more to OBSV or MRNS? In the previous week, ObsEva and ObsEva both had 1 articles in the media. ObsEva's average media sentiment score of 0.00 equaled Marinus Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marinus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OBSV or MRNS more profitable? ObsEva has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. ObsEva's return on equity of -416.36% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Do insiders & institutionals believe in OBSV or MRNS? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor OBSV or MRNS? Marinus Pharmaceuticals received 118 more outperform votes than ObsEva when rated by MarketBeat users. Likewise, 66.62% of users gave Marinus Pharmaceuticals an outperform vote while only 50.39% of users gave ObsEva an outperform vote. CompanyUnderperformOutperformObsEvaOutperform Votes31950.39% Underperform Votes31449.61% Marinus PharmaceuticalsOutperform Votes43766.62% Underperform Votes21933.38% Which has more volatility and risk, OBSV or MRNS? ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Do analysts rate OBSV or MRNS? Marinus Pharmaceuticals has a consensus price target of $4.79, indicating a potential upside of 771.56%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Which has higher earnings and valuation, OBSV or MRNS? ObsEva has higher earnings, but lower revenue than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEva$20.11M0.00-$58.38M-$0.92N/AMarinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22 SummaryMarinus Pharmaceuticals beats ObsEva on 9 of the 16 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.115.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net Income-$58.38M$138.55M$3.19B$245.94M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastMRNSMarinus Pharmaceuticals4.2119 of 5 stars$0.55+0.1%$4.79+770.1%-94.4%$30.37M$31.47M-0.22110Analyst ForecastPMNProMIS Neurosciences0.3443 of 5 stars$0.93-5.0%N/A-62.4%$30.27MN/A-9.265News CoverageVRCAVerrica Pharmaceuticals3.9342 of 5 stars$0.66-0.7%$9.50+1,342.0%-85.2%$30.04M$5.12M-0.3640Gap UpSNYRSynergy CHC Corp. (Uplisting)N/A$3.43-10.7%$10.00+191.5%N/A$29.86M$26.01M0.0040Gap UpLEXXLexaria Bioscience3.4102 of 5 stars$1.70-4.5%$9.50+458.8%-35.6%$29.84M$460,000.00-3.407AKTXAkari TherapeuticsN/A$1.12-9.4%N/A-58.6%$29.76MN/A0.009Analyst ForecastNews CoverageGap DownXLOXilio Therapeutics3.2453 of 5 stars$0.67-1.5%$4.00+497.0%+63.2%$29.45MN/A-0.3970GDTCCytoMed Therapeutics2.2476 of 5 stars$2.69-4.3%$5.00+85.9%+18.1%$29.43MN/A0.00N/ABFRGBullfrog AI0.2526 of 5 stars$3.36+17.5%N/A-32.1%$29.27M$60,000.00-3.954High Trading VolumeJATTJATT AcquisitionN/A$1.66-6.2%N/A-61.9%$28.64MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Marinus Pharmaceuticals Alternatives ProMIS Neurosciences Alternatives Verrica Pharmaceuticals Alternatives Synergy CHC Corp. (Uplisting) Alternatives Lexaria Bioscience Alternatives Akari Therapeutics Alternatives Xilio Therapeutics Alternatives CytoMed Therapeutics Alternatives Bullfrog AI Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OBSV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
